3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
100
Carcinoma, Non-Small-Cell Lung
48
Neoplasms
34
Urinary Bladder Neoplasms
25
Lung Neoplasms
25
Cholangiocarcinoma
23
Breast Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
18
Lymphoma, Non-Hodgkin
13
Lymphoma
13
Recurrence
12
Lymphoma, Large B-Cell, Diffuse
11
Biliary Tract Neoplasms
11
Sarcoma
10
Carcinoma, Transitional Cell
9
Hodgkin Disease
8
Gallbladder Neoplasms
8
Fallopian Tube Neoplasms
8
Adenocarcinoma
8
Bile Duct Neoplasms
7
Colorectal Neoplasms
6
Triple Negative Breast Neoplasms
5
Lymphoma, Follicular
5
Liver Neoplasms
5
Head and Neck Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Small Cell Lung Carcinoma
4
Interventions
Docetaxel
3
nimotuzumab
1
WW Domain-Containing Oxidoreductase
1
Vinorelbine
1
Paclitaxel
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Carboplatin
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Non-Small Cell Lung Cancer
×
Gemcitabine
×
Clear all
NCT00345059
2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3
Terminated
84 enrolled